Hard To Treat Diseases (HTDS) Obtains HAS Certificate

SHENZHEN, China, April 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com China based operating subsidiary Mellow Hope has obtained the HAS certificate (Halal Assurance system) issued by the Hangzhou Muslim Association. The HAS covers Group ACYW135 and A+C Meningococcal Polysaccharide Vaccine and Flu vaccine. Mr. Terry Yuan CEO said "With this certificate, we can export all our products to all the Muslim countries. Last year, we had successfully bid the tender of 75,000 vials of Group ACYW135 Meningococcal Polysaccharide Vaccine in Indonesia, and the tender for 300,000 vials of the same application is in the process. We are hopeful that our successful tender experience of last year, will assist Mellow Hope to win the tender again this year."

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.